FrancophonIA/ELRC3.0 huggingface dataset:
English: Based on theoretical considerations REZOLSTA is expected to increase lumefantrine plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab lumefantriini plasmakontsentratsioone.
English: Based on theoretical considerations REZOLSTA may alter warfarin plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA võib muuta varfariini plasmakontsentratsioone.
English: Based on theoretical considerations REZOLSTA is expected to increase metformin plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab metformiini plasmakontsentratsioone.
English: General disorders and administration site conditions Common fatigue, asthenia
Estonian: Üldised häired ja manustamiskoha reaktsioonid Sage väsimus, asteenia
English: Concentrations of voriconazole may increase or decrease when co-administered with REZOLSTA.
Estonian: REZOLSTA-ga koos manustamisel võib vorikonasooli plasmakontsentratsioon suureneda või väheneda.
English: Increased CPK, myalgia, myositis and, rarely, rhabdomyolysis have been reported with the use of HIV protease inhibitors, particularly in combination with NRTIs.
Estonian: HIV proteaasi inhibiitorite kasutamisel on kirjeldatud kreatiinfosfokinaasi (CPK) aktiivsuse suurenemist, müalgiat, müosiiti ja harva rabdomüolüüsi, eriti kui neid kombineeritakse NRTI-dega.
English: Treatment-experienced darunavir/cobicistat 800/150 mg once daily N = 18
Estonian: Varem ravitud patsiendid, darunaviir/ko bitsistaat 800/150 mg üks kord ööpäevas N = 18
English: Based on theoretical considerations REZOLSTA is expected to increase these anti-depressant plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab nende antidepressantide plasmakontsentratsioone.
English: Based on theoretical considerations etravirine is expected to decrease darunavir and/or cobicistat plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et etraviriin vähendab darunaviiri ja/või kobitsistaadi plasmakontsentratsioone.
English: Hepatotoxicity
Estonian: ANTATSIIDID
English: Clinical monitoring is recommended when co-administering REZOLSTA with beta-blockers and a lower dose of the beta-blocker should be considered.
Estonian: REZOLSTA koosmanustamisel nende beetablokaatoritega on soovitatav kliiniline jälgimine ja tuleb kaaluda beetablokaatori väiksemaid annuseid.
English: Based on theoretical considerations these antimycobacterials are expected to decrease darunavir and/or cobicistat plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et need mükobakterivastased ravimid vähendavad darunaviiri ja/või kobitsistaadi plasmakontsentratsioone.
English: Treatment-experienced darunavir/ritonavir 800/100 mg once daily N = 294
Estonian: Varem ravitud patsiendid, darunaviir/ritona viir 800/100 mg üks kord ööpäevas N = 294
English: Treatment-naïve darunavir/cobicistat 800/150 mg once daily N = 295
Estonian: Varem ravimata patsiendid, darunaviir/ko bitsistaat 800/150 mg üks kord ööpäevas N = 295
English: Uncommon immune reconstitution inflammatory syndrome
Estonian: Aeg-ajalt immuunsüsteemi reaktivatsiooni sündroom
English: Based on theoretical considerations REZOLSTA is expected to increase alfentanil plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab alfentanüüli plasmakontsentratsioone.
English: Outcomes darunavir/ ritonavir 800/100 mg once daily N = 343
Estonian: Tulemused darunaviir/ ritonaviir 800/100 mg üks kord ööpäevas N = 343
English: Based on theoretical considerations REZOLSTA is expected to increase salmeterol plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab salmeterooli plasmakontsentratsioone.
English: Caution should be exercised when combining one of these anti-neoplastic agents with REZOLSTA.
Estonian: Nende kasvajavastaste ravimite kombineerimisel REZOLSTA-ga tuleb olla ettevaatlik.
English: Based on theoretical considerations REZOLSTA may increase plasma concentrations of these analgesics.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA võib suurendada nende valuvaigistite plasmakontsentratsioone.
English: Based on theoretical considerations REZOLSTA is expected to increase these antiarrhythmic plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab nende antiarütmikumide plasmakontsentratsioone.
English: Posology
Estonian: Tabletituum
English: Alternative or additional contraceptive measures are recommended when oestrogen based contraceptives are co administered with REZOLSTA.
Estonian: Östrogeenipõhiste rasestumisvastaste vahendite kasutamisel samaaegselt REZOLSTA-ga on soovitatav kasutada teisi või täiendavaid kontratseptsioonimeetodeid.
English: No mechanistic interaction expected based on theoretical consideration.
Estonian: Teoreetiliste kaalutluste alusel ei ole toimemehhanismiga seotud koostoimeid oodata
English: Among 1,968 treatment-experienced patients receiving darunavir co-administered with ritonavir 600/100 mg twice daily, 236 patients were co-infected with hepatitis B or C. Co-infected patients were more likely to have baseline and treatment emergent hepatic transaminase elevations than those without chronic viral hepatitis (see section 4.4).
Estonian: Darunaviiri ja sellega koos manustatavat ritonaviiri (600/100 mg kaks korda ööpäevas) kasutanud 1968 eelnevalt ravitud patsiendi hulgas oli B- või C-hepatiiti nakatunuid 236.
English: - Bosentan (to treat high blood pressure in the pulmonary circulation) - Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, midazolam when used as injection (medicines to treat trouble with sleeping and/or anxiety) - Metformin (to treat type 2 diabetes) - Fentanyl, oxycodone, tramadol (to treat pain).
Estonian: (depressiooni ja ärevuse raviks), - maravirok (HIV infektsiooni raviks), - kolhitsiin (podagra või perekondliku Vahemere palaviku raviks).Kui teil on neeru ja/või maksakahjustus vt lõik „Ärge kasutage REZOLSTA-t koos järgmiste ravimitega“; - bosentaan (kopsuvereringes kõrge vererõhu raviks), - buspiroon, klorasepaat, diasepaam, estasolaam, flurasepaam, solpideem, midasolaam süstena kasutamisel (ravimid unehäirete ja/või ärevuse raviks), - metformiin (2. tüüpi suhkurtõve raviks), - fentanüül, oksükodoon, tramadool (valu raviks).
English: Based on theoretical considerations REZOLSTA is expected to increase rilpivirine plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab rilpiviriini plasmakontsentratsioone.
English: Tablet film-coat
Estonian: Tableti õhuke polümeerikate
English: Consideration should be given to official guidance on the appropriate treatment of tuberculosis in HIV infected patients.
Estonian: HIV-iga nakatunud patsientidele sobiva tuberkuloosiravi tagamiseks tuleb lähtuda kohalikest juhistest.
English: If you notice any of these symptoms please inform your doctor.
Estonian: Teavitage oma arsti, kui te märkate endal mõnda neist sümptomitest.
English: Based on theoretical considerations REZOLSTA is expected to increase colchicine plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab kolhitsiini plasmakontsentratsioone.
English: Treatment-experienced darunavir/cobicistat 800/150 mg once daily + OBR N = 18
Estonian: Varem ravitud patsiendid, darunaviir/kobitsistaa t 800/150 mg üks kord ööpäevas + OBR N = 18
English: Treatment-naïve darunavir/cobicistat 800/150 mg once daily + OBR N = 295
Estonian: Varem ravimata patsiendid, darunaviir/kobitsistaa t 800/150 mg üks kord ööpäevas + OBR N = 295
English: Esomeprazole
Estonian: Posakonasool
English: Based on theoretical considerations REZOLSTA is expected to increase these anti-neoplastic plasma concentrations.
Estonian: Teoreetiliste kaalutluste alusel eeldatakse, et REZOLSTA suurendab nende kasvajavastaste ravimite plasmakontsentratsioone.
English: This recommendation is different from ritonavir-boosted darunavir.
Estonian: Ritonaviiriga võimendatud darunaviiri puhul kehtib teine soovitus.
English: Clinical monitoring is recommended when co-administering REZOLSTA with clonazepam.
Estonian: REZOLSTA samaaegsel manustamisel klonasepaamiga on soovitatav kliiniline jälgimine.
English: Limited data is available in patients with HIV-1 clades other than B.
Estonian: Andmed patsientide kohta, kelle HIV-1
English: HIV PI darunavir amprenavir atazanavir indinavir lopinavir saquinavir tipranavir
Estonian: Abakaviir Emtritsitabiin Lamivudiin Stavudiin Zidovudiin
English: Xultophy is given once a day, preferably at the same time each day.
Estonian: Xultophyt manustatakse üks kord ööpäevas, eelistatavalt iga päev samal ajal.
English: Further information on Xultophy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Xultophy kohta on ameti veebilehel ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Xultophy received a marketing authorisation valid throughout the EU on 18 September 2014.
Estonian: Xultophy on saanud müügiloa, mis kehtib kogu ELis, 18. septembril 2014.
English: What measures are being taken to ensure the safe and effective use of Xultophy?
Estonian: Mis meetmed võetakse, et tagada Xultophy ohutu ja efektiivne kasutamine?
English: The European Medicines Agency decided that Xultophy's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Xultophy kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Other information about Xultophy
Estonian: Muu teave Xultophy kohta
English: As for all medicines, data on the use of Xultophy are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Xultophy kasutamise kohta pidevat järelevalvet.
English: Side effects on the digestive system occurred in up to 1 in 10 patients and included nausea (feeling sick), diarrhoea, vomiting, constipation, dyspepsia (indigestion), gastritis (inflammation of the stomach), abdominal pain (stomach ache), flatulence (wind), gastroesophageal reflux disease (passage of stomach acid back up towards the mouth), and distension (swelling) of the belly.
Estonian: Kuni 1 patsiendil 10st esines seedeelundkonda mõjutanud kõrvalnähte, sealhulgas iiveldus, kõhulahtisus, oksendamine, kõhukinnisus, düspepsia (seedehäire), gastriit (maopõletik), kõhuvalu, kõhupuhitus, gastroösofageaalne reflukshaigus (maohappe tagasivool söögitorusse) ja kõhu paisumine.
English: Patients in the study either continued with their current treatment or received Xultophy instead of the GLP-1 agonist.
Estonian: Uuringus osalenud patsiendid jätkasid senist ravi või said GLP-1 agonisti asemel Xultophyt.
English: In the group using insulin degludec it fell from 8.8% to 8.0%.
Estonian: Degludekinsuliini kasutanud rühmas langes see 8,8%-lt 8,0%-le.
English: Xultophy (insulin degludec / liraglutide)
Estonian: Xultophy (degludekinsuliin/liraglutiid)
English: In the group that kept on receiving the GLP-1 agonist, it fell from 7.7% to 7.4%.
Estonian: GLP-1 agonistiga ravi jätkanud rühmas langes see 7,7%-lt 7,4%-le.
English: Side effects reported with Xultophy are carefully evaluated and any necessary action taken to protect patients.
Estonian: Xultophy kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Xultophy is a medicine that is used for the treatment of type 2 diabetes.
Estonian: Xultophy on ravim, mida kasutatakse II tüüpi diabeedi raviks.
English: Type 2 diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose, or the body is unable to use insulin effectively.
Estonian: II tüüpi diabeet on haigus, mille korral organismis ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: What is Xultophy and what is it used for?
Estonian: Mis on Xultophy ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xultophy have also been included in the summary of product characteristics and the package leaflet.
Estonian: Xultophy ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The company that markets Xultophy will provide educational materials for healthcare professionals, explaining how to use the medicine safely, so as to reduce the risk of medication errors.
Estonian: Lisaks varustab Xultophyt turustav ettevõte tervishoiuspetsialistid teabematerjaliga, mis sisaldab teavet ravimi ohutu kasutamise kohta, et vähendada ravivigade riski.
English: The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the medicine work less well than expected.
Estonian: Süstekohta peab iga süste korral muutma, et vältida nahamuutusi (nt nahapaksendeid), mis võivad vähendada ravimi toimet.
English: For more information about using Xultophy, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Xultophy kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The most common side effect with Xultophy (which may affect more than 1 in 10 people) is hypoglycaemia (low blood glucose).
Estonian: Xultophy kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on hüpoglükeemia (vere väike glükoosisisaldus).
English: Why is Xultophy approved?
Estonian: Miks Xultophy heaks kiideti?
English: Insulin degludec is slightly different from human insulin as it is absorbed more slowly and regularly by the body after an injection and it works for a long time.
Estonian: Degludekinsuliin erineb iniminsuliinist selle poolest, et see imendub organismis pärast süstimist aeglasemalt ja ühtlasemalt ning tal on pikk toimeaeg.
English: The majority of patients treated with Xultophy in these studies achieved control of their blood glucose (HbA1c below 7.0%) and many achieved HbA1c below 6.5%.
Estonian: Nendes uuringutes õnnestus reguleerida enamiku Xultophyga ravitud patsientide vere glükoosisisaldust (HbA1c alla 7,0%) ja paljude HbA1c sisaldus vähenes alla 6,5%.
English: It acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food.
Estonian: See toimib sarnaselt sooles tekkivate hormoonide inkretiinidega, suurendades toidu mõjul kõhunäärme eritatava insuliini kogust.
English: One of the active substances in Xultophy, insulin degludec, is a replacement insulin that acts in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Estonian: Xultophy üks toimeaineid degludekinsuliin on asendusinsuliin, mis toimib samal viisil kui organismis tekkiv insuliin, aidates glükoosil siseneda verest rakkudesse.
English: Adding this medicine to other diabetes medicines offers better control of blood glucose and having an alternative treatment option is valuable in individualising treatment.
Estonian: Komitee leidis, et Xultophy lisamine teistele diabeediravimitele aitab vere glükoosisisaldust paremini reguleerida ja ravi individuaalse kohandamise seisukohast on oluline alternatiivse ravivõimaluse olemasolu.
English: What are the risks associated with Xultophy?
Estonian: Mis riskid Xultophyga kaasnevad?
English: The other active substance in Xultophy, liraglutide, belongs to the class of diabetes medicines known as GLP-1 agonists.
Estonian: Xultophy teine toimeaine liraglutiid kuulub diabeediravimite GLP-1 agonistide rühma.
English: How does Xultophy work?
Estonian: Kuidas Xultophy toimib?
English: For the full list of side effects and restrictions with Xultophy, see the package leaflet.
Estonian: Xultophy kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Treatment with Xultophy and metformin was compared with treatment using insulin degludec and metformin.
Estonian: Xultophy ja metformiini ravi võrreldi degludekinsuliini ja metformiini raviga.
English: • The first study involved 1,663 patients whose diabetes was not adequately controlled with the diabetes medicines metformin or metformin and pioglitazone taken by mouth.
Estonian: • Esimeses uuringus osales 1663 patsienti, kelle haigus ei olnud ainult suukaudsete diabeediravimite metformiini või metformiini ja pioglitasooni kombinatsiooniga piisavalt reguleeritud.
English: • The third study involved 438 patients whose blood glucose was not adequately controlled by a combination of a GLP-1 agonist (liraglutide or exenatide) and metformin with or without other diabetes medicines taken by mouth.
Estonian: • Kolmandas uuringus osales 438 patsienti, kelle vere glükoosisisaldus ei olnud ainult GLP-1 agonisti (liraglutiidi või eksenatiidi) ja metformiini kombinatsiooniga (manustatuna koos teiste suukaudsete diabeediravimitega või ilma) piisavalt reguleeritud.
English: In all studies, the main measure of effectiveness was the change after 6 months of treatment in the level in the blood of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
Estonian: Kõigis uuringuis oli efektiivsuse põhinäitaja vere glükoosisisalduse reguleeritavust näitava aine glükohemoglobiini (HbA1c) sisalduse muutus 6 ravikuu järel.
English: The average HbA1c level, which was 8.3% at the start, fell to 6.4% after 26 weeks of treatment with Xultophy, compared with 6.9% and 7.0% respectively with insulin degludec and liraglutide.
Estonian: Keskmine HbA1c tase, mis oli algul 8,3%, langes 26-nädalase Xultophy ravi järel 6,4%-le võrreldes 6,9%-ga degludekinsuliini ja 7,0%-ga liraglutiidi kasutamisel.
English: An overview of Xultophy and why it is authorised in the EU
Estonian: Ülevaade ravimist Xultophy ja ELis müügiloa väljastamise põhjendus
English: Patients can inject themselves with Xultophy if they have been trained appropriately.
Estonian: Kui patsiendid on saanud asjakohase väljaõppe, tohivad nad endale Xultophyt ise süstida.
English: Average HbA1c at the start was 8.7% in the Xultophy group, and fell after 26 weeks of treatment to 6.9%.
Estonian: Keskmine HbA1c sisaldus oli Xultophy rühmas algul 8,7% ja see langes 26-nädalase ravi järel 6,9%-le.
English: The active substances in Xultophy are insulin degludec and liraglutide.
Estonian: Xultophy toimeained on degludekinsuliin ja liraglutiid.
English: How is Xultophy used?
Estonian: Kuidas Xultophyt kasutatakse?
English: It is given as an injection under the skin of the thigh, the upper arm or the abdomen (belly).
Estonian: Seda süstitakse subkutaanselt reide, õlavarde või kõhtu.
English: • The second study involved 413 patients whose blood glucose was not adequately controlled by insulin and metformin with or without other diabetes medicines taken by mouth.
Estonian: • Teises uuringus osales 413 patsienti, kelle vere glükoosisisaldus ei olnud ainult insuliini ja metformiiniga (manustatuna koos teiste suukaudsete diabeediravimitega või ilma) piisavalt reguleeritud.
English: Average HbA1c was 7.8% before patients started to receive Xultophy, and fell after 26 weeks of treatment to 6.4%.
Estonian: Keskmine HbA1c sisaldus oli enne Xultophy manustamist patsientidel 7,8% ja see langes 26-nädalase ravi järel 6,4%-le.
English: What benefits of Xultophy have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Xultophy kasulikkus?
English: Adding Xultophy to their treatment was compared with adding either of its active substances, insulin degludec or liraglutide.
Estonian: Xultophy lisamist nende raviskeemi võrreldi Xultophy kummagi toimeaine, degludekinsuliini ja liraglutiidi eraldi lisamisega.
English: Together with diet and exercise, Xultophy is added to treatment with diabetes medicines taken by mouth when these medicines, alone or with other injections, have not controlled blood glucose (sugar) levels.
Estonian: Seda kasutatakse koos dieedi ja füüsilise koormusega lisaks suukaudsetele diabeediravimitele patsientidel, kelle vere glükoosisisaldus (nn veresuhkur) ei ole ainult nende ravimitega või kombinatsioonis teiste süstidega piisavalt reguleeritud.
English: Once-daily injection of Xultophy has been shown to be of benefit in controlling blood glucose in three main studies involving 2,514 patients with type 2 diabetes.
Estonian: Kolmes põhiuuringus, milles osales 2514 II tüüpi diabeediga patsienti, tõendati, et Xultophy süstimine üks kord ööpäevas aitab reguleerida vere glükoosisisaldust.
English: Xultophy is available as pre-filled disposable pens and can only be obtained with a prescription.
Estonian: Xultophyt turustatakse eeltäidetud ühekordsetes pensüstaldes.
English: The vaccination schedule depends on the age of the child and should be based on official recommendations:
Estonian: Vaktsineerimisskeem sõltub lapse vanusest ning see peab põhinema ametlikel soovitustel.
English: The full EPAR for Prevenar 13 can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst vaktsiini Prevenar 13 kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Prevenar 13 contains the polysaccharides from 13 different types of S. pneumoniae (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F).
Estonian: Prevenar 13 sisaldab bakteri S. pneumoniae 13 eri tüübi (serotüübid 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F ja 23F) polüsahhariide.
English: The fourth dose, the booster, is given between 11 and 15 months of age.
Estonian: Neljas (tugevdav) annus antakse 11-15 kuu vanuses.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Prevenar 13 on 9 December 2009.
Estonian: Euroopa Komisjon andis vaktsiini Prevenar 13 müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 9. detsembril 2009.
English: The studies compared the immune responses one month after vaccination with the two vaccines.
Estonian: Uuringutes võrreldi immuunvastuseid üks kuu pärast vaktsineerimist kummagi vaktsiiniga.
English: A risk management plan has been developed to ensure that Prevenar 13 is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada vaktsiini Prevenar 13 võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Prevenar 13?
Estonian: Mis meetmed võetakse, et tagada vaktsiini Prevenar 13 ohutu ja efektiivne kasutamine?
English: Prevenar 13 is very similar to Prevenar but contains six additional polysaccharides from serotypes which are responsible for between 16 and 60% of the cases.
Estonian: Prevenar 13 on väga sarnane Prevenariga, kuid sisaldab 6 täiendavat polüsahhariidi nendest serotüüpidest, mis põhjustavad 16-60% haigustest.
English: In Europe, it is estimated that these are responsible for between 73 and 100% of the cases of invasive disease in children under the age of five years, and at least 50 - 76% of the cases of invasive disease in adults, depending on the country.
Estonian: Need tüübid põhjustavad Euroopas sõltuvalt riigist hinnanguliselt ligikaudu 73-100% alla 5-aastaste laste invasiivsete haiguste juhtudest ja vähemalt 50-76% täiskasvanute invasiivsete haiguste juhtudest.
English: pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Estonian: pneumokoki konjugeeritud polüsahhariidvaktsiin (13-valentne, adsorbeeritud)
English: • children aged between six weeks and six months are normally given four doses.
Estonian: • Lastele vanuses 6 nädalat kuni 6 kuud antakse tavaliselt 4 annust.